References
- Milkins C, Berryman J, Cantwell C, et al. Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories. British Committee for Standards in Hematology. Transfus Med. 2013;23(1):3–35. doi:10.1111/j.1365-3148.2012.01199.x23216974
- Basu S, Kaur R, Kaur G. Hemolytic disease of the fetus and newborn: current trends and perspectives. Asian J Transfus Sci. 2011;5(1):3–7. doi:10.4103/0973-6247.7596321572705
- Chavez GF, Mulinare J, Edmonds LD. Epidemiology of Rh hemolytic disease of the newborn in the United States. J Am Med Assoc. 1991;265(24):3270–3274. doi:10.1001/jama.1991.03460240066029
- Liumbruno GM, D’alessandro A, Rea F, et al. The role of antenatal immunoprophylaxis in the prevention of maternal foetal anti Rh (D) alloimmunisation. Blood Transfus. 2010;8(1):8–16. doi:10.2450/2009.0108-0920104273
- Hassan MN, Mohd Noor NH, Johan Noor SR, et al. Hemolytic disease of fetus and newborn due to maternal red blood cell alloantibodies in the Malay population. Asian J Transfus Sci. 2014;8(2):113–117. doi:10.4103/0973-6247.13744925161351
- Dajak S, Stefanović V, Capkun V. Severe hemolytic disease of fetus and newborn caused by red blood cell antibodies undetected at first-trimester screening. Transfusion. 2011;51(7):1380–1388. doi:10.1111/j.1537-2995.2010.03006.x21214583
- Smith HM, Shirey RS, Thoman SK, Jackson JB. Prevalence of clinically significant red blood cell alloantibodies in pregnant women at a large tertiary-care facility. Immunohematology. 2013;29(4):127–130.24689681
- de Vrijer B, Harthoorn-Lasthuizen EJ, Oosterbaan HP. The incidence of irregular antibodies in pregnancy: a prospective study in the region of the ‘s-Hertogenbosch. Ned Tijdschr Geneeskd. 1999;143(50):2523–2527.10627755
- Solves P, Gomez-Segui I, Guinot M, et al. Prevalence of red cell antibodies in pregnant women and hemolytic disease of newborn in a tertiary care hospital. ARC J Gynaecol Obstet. 2017;2(2):18–22.
- Jeremiah ZA, Mordi A, Buseri FI, Adias TC. Frequencies of maternal red blood cell alloantibodies in Port Harcourt, Nigeria. Asian J Transfus Sci. 2011;5(1):39–41. doi:10.4103/0973-6247.7598721572714
- Erikstein BS, Hagen KG, Hervig T. RBC alloantibody prevalence and specificity in a Western Norwegian tertiary hospital. Transfus Med. 2018. doi:10.1111/tme.12511
- Pal M, Williams B. Prevalence of maternal red cell alloimmunisation: a population study from Queensland, Australia. Pathology. 2015;47(2):151–155. doi:10.1097/PAT.000000000000022525551305
- Lee CK, Ma ES, Tang M, Lam CCK, Lin CK, Chan LC. Prevalence and specificity of clinically significant red cell alloantibodies in Chinese women during pregnancy-a review of cases from 1997 to 2001. Transfus Med. 2003;13(4):227–231.12880393
- Judd WJ; The 2003-2004 Scientific Section Coordinating Committee. Guidelines for Prenatal and Perinatal Immunohematology. 1st ed. Bethesda, MD: AABB; 2005.
- Koelewijn JM, Vrijkotte TGM, van der Schoot CE, Bonsel GJ, de Haas M. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion. 2008;48(5):941–952. doi:10.1111/j.1537-2995.2007.01625.x18248570
- Shahverdi E, Moghaddam M, Gorzin F. Maternal red blood cell alloantibodies identified in blood samples obtained from Iranian pregnant women: the first population study in Iran. Transfusion. 2017;57(1):97–101. doi:10.1111/trf.1386728097699
- Vaughan JI, Warwick R, Letsky E, Nicolini U, Rodeck CH, Fisk NM. Erythropoietic suppression in fetal anemia because of Kell alloimmunization. Am J Obstet Gynecol. 1994;171(1):247–252. doi:10.1016/0002-9378(94)90477-48030708
- Weiner CP, Widness JA. Decreased fetal erythropoiesis and hemolysis in Kell hemolytic anemia. Am J Obstet Gynecol. 1996;174(2):547–551. doi:10.1016/s0002-9378(96)70425-88623782
- Heathcote DJ, Carroll TE, Flower RL. Sixty years of antibodies to MNS system hybrid glycophorins: what have we learned? Transfus Med Rev. 2011;25(2):111–124. doi:10.1016/j.tmrv.2010.11.00321345645
- Yasuda H, Ohto H, Nollet KE, et al. Hemolytic disease of the fetus and newborn with late-onset Anemia due to Anti-M: a case report and review of the Japanese literature. Transfus Med Rev. 2014;28(1):1–6. doi:10.1016/j.tmrv.2013.10.00224262303
- Wikman A, Edner A, Gryfelt G, Jonsson B, Henter J-I. Fetal hemolytic anemia and intrauterine death caused by anti-M immunization. Transfusion. 2007;47(5):911–917. doi:10.1111/j.1537-2995.2007.01209.x17465958